SpIntellx

Shaping the Future of
Spatially Intelligent Biology

See More. Know More.
Power Precision Pathology.

What if

you can empower researchers and clinicians to unravel the hidden connections in the tumor microenvironment through deep profiling cell-cell communication patterns and spatial relationships to dramatically improve patient outcomes?

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells.
Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows.

Transforming Drug Discovery and Clinical Development with Spatially Intelligent Biology

Accelerated Drug Discovery
Our solutions are the only ones in the market that identify novel cell types, biomarkers & targets leveraging unbiased spatial analytics and explainable AI
Optimized Clinical Trials
Our solutions achieve previously unattainable level of precision in patient stratification for clinical trials
Advanced Companion Diagnostics
Our precision pathology solutions create highly predictive companion diagnostics and prognostics
Personalized Therapeutic Options
Our solutions attain highly personalized adjuvant therapy options for individual patients and provide actionable insights to patient outcomes
Efficient and Accurate Clinical Workflows
Our solutions address the unmet pathology needs by bringing innovations and delivering unparalleled flexibility and ease

Accelerated Drug Discovery

Our solutions are the only ones in the market that identify novel cell types, biomarkers & targets leveraging unbiased spatial analytics and explainable AI

Optimized Clinical Trials

Our solutions achieve previously unattainable level of precision in patient stratification for clinical trials

Advanced Companion Diagnostics

Our precision pathology solutions create highly predictive companion diagnostics and prognostics

Personalized Therapeutic Options

Our solutions attain highly personalized adjuvant therapy options for individual patients and provide actionable insights to patient outcomes

Efficient and Accurate Clinical Workflows

Our solutions address the unmet pathology needs by bringing innovations and delivering unparalleled flexibility and ease

Leveraging Unbiased Spatial Analytics and Explainable AI (xAI) to Get to the “Why?”

We are entering a new era of precision pathology fueled by explainable AI and spatial intelligence to reveal more of the complex circuitry of cancer. In a short period of time, SpIntellx has totally transformed the landscape of computational pathology with our proprietary technologies significantly beyond the first-generation players who are in the market today"

D. Lansing Taylor, PhD

EXECUTIVE CHAIRMAN & CO-FOUNDER

Are you leveraging the power of

Precision Pathology?

Learn more about why explainable AI and next generation spatial analytics make a
difference in precision pathology

Download Whitepaper

Download Whitepaper

Subscribe to our Newsletter

* indicates required

S. Chakra Chennubhotla, PhD

PRESIDENT, CO-FOUNDER, &
CHIEF TECHNOLOGY OFFICER

Chakra earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Chakra was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.

Chakra co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Chakra’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.

Submit your Resume

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Bill Newlin

BOARD MEMBER & INVESTOR

Bill graduated from Princeton University, has received the University of Pittsburgh Law School’s distinguished alumni award and was awarded an honorary doctorate of business administration degree from Robert Morris University.

Mr. William R. Newlin is Chairman of Newlin Investment Company, which he founded in 2007. Mr. Newlin is a SpIntellx Board Member and Investor. A seasoned executive and entrepreneur, Bill was the Executive Vice President and Chief Administrative Officer for DICK’S Sporting Goods, Inc. (NYSE: DKS), a full-line sports and fitness retailer with more than 600 stores; and Chairman and Chief Executive Officer for Buchanan Ingersoll, one of the 100 largest law firms in the U.S. Bill was also Co-Founder of CEO Venture Funds, Founding Director of the Pittsburgh Technology Council and a Director of the Pittsburgh Life Sciences Greenhouse.

D. Lansing Taylor, PhD

EXECUTIVE CHAIRMAN & CO-FOUNDER

Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.

Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.